COMP <GO>
KROS vs NATR // EV/EBITDA & P/E VALUATION
Keros Therapeutics Inc. (NASDAQ) VS. Nature's Sunshine Products Inc. (NASDAQ) • 15-METRIC TALLY: KROS 5
— NATR 2
■ METRIC PARITY
LAST: $11.04 (-2.82%) • MKT CAP: $225.2M
valuation
—
LAST: $12.25 (-0.24%) • MKT CAP: $216.1M
valuation
4.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KROS VS. NATR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KROS | NATR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 72.40% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 28.90% | +56.10 | KROS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 4.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 13.35% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 27.70% | 5.20% | +22.50 | KROS | /operating-margins <GO> |
| Net Profit Margin | 35.70% | 4.10% | +31.60 | KROS | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 5.70% | +174.30 | KROS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.31 | 4.33 | -0.02 | NATR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.6 | 41.8 | -1.19 | NATR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 10.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $225.2M | $216.1M | $9.2M | KROS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KROS REV | NATR REV | KROS GROSS % | NATR GROSS % | KROS FCF | NATR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $244.1M | $480.1M | — | 72.4% | $106.0M | $28.8M |
| FY 2024 | $3.5M | $454.4M | — | 71.5% | -$162.8M | $14.3M |
| FY 2023 | $151.0K | $445.3M | — | — | -$124.5M | $41.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KROS // BETA —
NATR // BETA —